vTv expands HPP737 license to worldwide; Newsoara pays $20M upfront, up to $115M milestones plus royalties

vTv Therapeutics Inc.

Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.
Up to $50M in development milestones and $65M in sales-based milestones; royalties mid-single digits.
Prior amendment became null and void in June 2025; this replaces it.
Agreement with Newsoara Biopharma Co., Ltd., a Chinese partner.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

vTv Therapeutics Inc. entered into Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. valued at $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m (effective 2026-01-30).

Action: entry
Agreement: license
Counterparty: Newsoara Biopharma Co., Ltd.
Value: $20 million upfront fee, up to $50 million in development milestones, $65 million in sales-related m
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”) to amend the License Agreement previously entered into between vTv LLC and Newsoara on May 31, 2018 (the “Original Agreement”).

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-26-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.